www.buynetmeds.com
Has www.buynetmeds.com received an FDA warning letter? Yes. FDA issued a warning letter dated June 12, 2025 concerning products containing semaglutide.
Letter facts
- Letter date
- June 12, 2025 (2025-06-12)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Products named
- Tapentadol (Asmanol 100mg)Tapentadol (Aspadol 50mg/75mg/100mg)Tapentadol (Etadol 100mg)Tapentadol (Noosanta 100mg)Tapentadol (Rin Tapenta 50mg)Tapentadol (Tapaday 50mg/100mg)Tapentadol (Tapal 100mg / Tapal-ER 100mg)Tapentadol (Tapedac 100mg)Tapentadol (Tapenax ER 50mg)Tapentadol (Tapfree ER 100mg)Tapentadol (Tapidol 50mg/100mg)Tapentadol (Tapsmart 100mg)Tapentadol (Topcynta 50mg/100mg)Tapentadol (Tprexadol 100mg)Tapentadol (Tydol 50mg/100mg)Tapentadol (Typendol 100mg)Tapentadol (Yenta 100mg)Semaglutide (Rybelsus 3mg/7mg/14mg tablets)Semaglutide (Semaglutida Tabletas)Semaglutide 0.25 mg Injection (Fitaro 0.25)Semaglutide 0.5 mg Injection (Fitaro 0.5)Semaglutide 1 mg Injection (Fitaro 1)Semaglutide 1.7 mg Injection (Fitaro 1.7)Semaglutide 2.4 mg Injection (Fitaro 2.4)
- Violation categories
- Unapproved new drugMisbranding
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
Factual Violation Summary
FDA says the website introduces into interstate commerce unapproved and misbranded semaglutide drug products, including injectable versions.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Unapproved new drugs
- Misbranded drugs
- Failure to bear adequate directions for use
- Unlawful sale of prescription drugs to U.S. consumers over the Internet
More letters about Retatrutide
Recent FDA warning letters concerning Retatrutide:
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
- Peptide Partners LLCAugust 24, 2026
- Peak Performance PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.